204 related articles for article (PubMed ID: 21395404)
21. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development.
Whitebread S; Hamon J; Bojanic D; Urban L
Drug Discov Today; 2005 Nov; 10(21):1421-33. PubMed ID: 16243262
[TBL] [Abstract][Full Text] [Related]
22. A holistic strategy for characterizing the safety of metabolites through drug discovery and development.
Walker D; Brady J; Dalvie D; Davis J; Dowty M; Duncan JN; Nedderman A; Obach RS; Wright P
Chem Res Toxicol; 2009 Oct; 22(10):1653-62. PubMed ID: 19715349
[TBL] [Abstract][Full Text] [Related]
23. Drug trafficking: recent advances in therapeutics and disease.
Sprowl JA; Sparreboom A
Clin Pharmacol Ther; 2012 Nov; 92(5):531-4. PubMed ID: 23085872
[TBL] [Abstract][Full Text] [Related]
24. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations.
Srinivas NR
Biomed Chromatogr; 2006 May; 20(5):383-414. PubMed ID: 16307470
[TBL] [Abstract][Full Text] [Related]
25. Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state.
Feng B; LaPerle JL; Chang G; Varma MV
Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):939-52. PubMed ID: 20433402
[TBL] [Abstract][Full Text] [Related]
26. Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites.
Dalvie D; Obach RS; Kang P; Prakash C; Loi CM; Hurst S; Nedderman A; Goulet L; Smith E; Bu HZ; Smith DA
Chem Res Toxicol; 2009 Feb; 22(2):357-68. PubMed ID: 19146377
[TBL] [Abstract][Full Text] [Related]
27. Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability.
Nassar AE; Kamel AM; Clarimont C
Drug Discov Today; 2004 Dec; 9(23):1020-8. PubMed ID: 15574318
[TBL] [Abstract][Full Text] [Related]
28. [Pharmacokinetic and metabolic studies in the development of drugs].
Vereczkey L
Acta Pharm Hung; 1995 Jul; 65(4):105-11. PubMed ID: 7572191
[TBL] [Abstract][Full Text] [Related]
29. Improved preclinical safety assessment using micro-BAL devices: the potential impact on human discovery and drug attrition.
Giri S; Bader A
Drug Discov Today; 2011 May; 16(9-10):382-97. PubMed ID: 21354326
[TBL] [Abstract][Full Text] [Related]
30. Utility of whole-body autoradioluminography in drug discovery for the quantification of tritium-labeled drug candidates.
Potchoiba MJ; Nocerini MR
Drug Metab Dispos; 2004 Oct; 32(10):1190-8. PubMed ID: 15377642
[TBL] [Abstract][Full Text] [Related]
31. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs.
Lappin G; Garner RC
Nat Rev Drug Discov; 2003 Mar; 2(3):233-40. PubMed ID: 12612650
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics/pharmacodynamics in drug development: an industrial perspective.
Chaikin P; Rhodes GR; Bruno R; Rohatagi S; Natarajan C
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1428-38. PubMed ID: 11185663
[TBL] [Abstract][Full Text] [Related]
33. Building predictive ADMET models for early decisions in drug discovery.
Penzotti JE; Landrum GA; Putta S
Curr Opin Drug Discov Devel; 2004 Jan; 7(1):49-61. PubMed ID: 14982148
[TBL] [Abstract][Full Text] [Related]
34. Hepatocytes--the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo.
Gómez-Lechón MJ; Castell JV; Donato MT
Chem Biol Interact; 2007 May; 168(1):30-50. PubMed ID: 17134688
[TBL] [Abstract][Full Text] [Related]
35. The pivotal role of drug metabolism and pharmacokinetics in the discovery and development of new medicines.
Alavijeh MS; Palmer AM
IDrugs; 2004 Aug; 7(8):755-63. PubMed ID: 15334309
[TBL] [Abstract][Full Text] [Related]
36. The impact of recent innovations in the use of liquid chromatography-mass spectrometry in support of drug metabolism studies: are we all the way there yet?
Nassar AE; Talaat RE; Kamel AM
Curr Opin Drug Discov Devel; 2006 Jan; 9(1):61-74. PubMed ID: 16445118
[TBL] [Abstract][Full Text] [Related]
37. Improving compound quality through in vitro and in silico physicochemical profiling.
van de Waterbeemd H
Chem Biodivers; 2009 Nov; 6(11):1760-6. PubMed ID: 19937820
[TBL] [Abstract][Full Text] [Related]
38. New horizons in drug metabolism, pharmacokinetics and drug discovery.
Palmer AM
Drug News Perspect; 2003; 16(1):57-62. PubMed ID: 12682673
[TBL] [Abstract][Full Text] [Related]
39. Predicting human pharmacokinetics from preclinical data.
Poggesi I
Curr Opin Drug Discov Devel; 2004 Jan; 7(1):100-11. PubMed ID: 14982153
[TBL] [Abstract][Full Text] [Related]
40. How pharmacogenomics (PG) are changing practice: implications for prescribers, their patients, and the healthcare system (PG series part I).
Preskorn SH; Hatt CR
J Psychiatr Pract; 2013 Mar; 19(2):142-9. PubMed ID: 23507814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
